Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec Compensation
confidence 85%
filed 2026-07-01
Item 5.02
The disclosure centers on a consulting agreement with F. Brad Denardo, the former President and CEO, establishing compensatory arrangements ($6,000 monthly consulting fee) for the Consulting Period (July 1, 2026 – June 30, 2027). While Denardo has already departed from executive roles, the principal disclosed action here is the formalization of his compensation structure as a consultant, not the departure itself. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-01
Item 7.01
The disclosure reports assay results from an infill drilling campaign at the Archimedes Underground Project, highlighting high-grade gold mineralization (e.g., "16.2 g/t Au over 56.4 Meters") and updates to the timing of feasibility studies. This is an operational/exploration milestone for a mining development project that would be material to investors evaluating the company's project advancement and resource expansion, but it does not fit the specific categories of earnings release, M&A activity, material impairment, or other defined event types. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and relates to ongoing project development and technical progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
Item 2.01
ExxonMobil completed a Redomiciliation Merger in which shareholders' shares were automatically exchanged for shares of ExxonMobil Holdings Corporation, a newly formed Texas corporation that replaced ExxonMobil as the publicly traded entity. The merger constitutes a material change of control and corporate reorganization, with the registrant's corporate form, domicile, and governing law changing and a new entity becoming the public parent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-01
Item 3.01
ExxonMobil Common Stock will be delisted from the NYSE following completion of the Redomiciliation Merger, with trading suspension on July 1, 2026 and expected delisting via Form 25 filing. The original ExxonMobil Common Stock will be replaced by ExxonMobil Holdings Corporation Common Stock trading under the same ticker.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-01
Item 5.02
ExxonMobil completed a comprehensive leadership transition effective at the Effective Time of the redomiciliation merger, with 12 directors resigning and 3 new directors (Neil A. Chapman, Neil A. Hansen, Jack P. Williams, Jr.) being elected, plus appointment of new named executive officers including James R. Chapman as President and Treasurer and Susan E. Buchanan as Vice President and Controller.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-07-01
Item 3.03
Item 3.03 discloses a material modification to security holders' rights by incorporating Item 2.01 content. The specific nature of the modification cannot be determined without access to the referenced Explanatory Note and Item 2.01 content, but the incorporation by reference indicates a material event affecting security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-01
Item 5.07
iAnthus held its 2026 Annual General Meeting of Shareholders on June 25, 2026, at which shareholders approved the election of five directors (Scott Cohen, Michelle Mathews-Spradlin, Kenneth W. Gilbert, Alexander Shoghi, and Richard Proud) and the re-appointment of PKF O'Connor Davies, LLP as the company's independent auditor.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-01
Item 8.01
The Board declared a distribution of $0.17 per share to common shareholders, payable on June 30, 2026. This is a routine but material dividend distribution typical of BDCs, which are required to distribute substantially all taxable income to shareholders. The declaration, amount, record date, and payment date are all clearly disclosed.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-07-01
Item 8.01
Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, with the company's common stock beginning trading on the OTC Basic Market on June 24, 2026 as a result of the bankruptcy filing.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-07-01
Item 4.01
The Audit Committee terminated Ernst & Young LLP as the Company's independent registered public accounting firm on June 25, 2026, following the Company's Chapter 11 bankruptcy filing.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses two compensatory arrangements for named executives: (1) a performance-based stock option award to CEO Arun Jeldi for 964,474 shares with market-capitalization-based vesting milestones, and (2) Change in Control Agreements with the CEO, CFO, and Chief Revenue Officer providing severance benefits upon qualifying terminations. These are classic executive compensation disclosures under Item 5.02(e), distinct from appointments or departures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
Item 2.01
The filing discloses completion of a disposition of a material asset—the sale of SITE Centers' ground leasehold interest and other interests in The Pike Outlets (Long Beach, California) to Pike Long Beach Owner LLC for $50.0 million in cash ($46.5 million net proceeds). This is a completed asset sale under Item 2.01 and represents a material capital transaction that would affect investor assessment of the company's asset base and liquidity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-01
Item 8.01
The Company exercised an option to prepay $50.0 million in principal of its 7.54% senior unsecured notes due July 28, 2026, with total payment of approximately $51.6 million including accrued interest. While this is technically a debt retirement rather than issuance, the materiality and financial significance of eliminating $50 million in outstanding debt obligations is substantial and affects the Company's capital structure and financial position. The prepayment eliminates all remaining Notes outstanding, making this a material capital event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
Box Inc held its Annual Meeting of stockholders on May 1, 2026, with voting results on four proposals: election of three Class III directors (Sue Barsamian, Jack Lazar, and Steve Murphy), advisory approval of named executive officer compensation, approval of an amendment to the 2015 Equity Incentive Plan increasing the share reserve by 7.2 million shares, and ratification of Ernst & Young LLP as independent auditor. All four proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 8.01
Curbline Properties entered into an underwriting agreement on June 29, 2026, to offer and sell 10,000,000 shares of common stock on a forward basis, with the offering closing on July 1, 2026. The company also entered into forward sale agreements with forward purchasers. This is a material dilutive equity issuance—a forward offering of common stock that will result in the delivery of 10 million shares within approximately 18 months, with net proceeds intended for general corporate purposes including property acquisitions, debt repayment, and capital expenditures. The magnitude and structure (forward sale with underwriter involvement) are hallmarks of a material capital-raising event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of TripAdvisor's annual stockholder meeting held June 29, 2026. The filing presents voting tallies for two proposals: (1) election of ten directors, with vote counts for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of KPMG LLP as independent auditor (For/Against/Abstain/Broker Non-Votes). All nominees were elected and the auditor appointment was ratified. This is a material governance event affecting investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-01
Item 8.01
This Item 8.01 disclosure concerns a material acquisition transaction—the merger of Whitestone REIT with AREG Wizard entities. The filing supplements the definitive proxy statement for a special shareholder meeting scheduled for July 9, 2026, to vote on the Mergers. The supplemental disclosures address shareholder litigation challenging proxy disclosures and provide additional details on the Board's process, financial advisor engagement, and fairness opinion—all core elements of M&A activity disclosure. Although technically filed under Item 8.01 (Other Events), the substance is the pending completion of a material change-of-control transaction.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-01
Item 5.02
Christopher C. Work, Chief Financial Officer of Zumiez Inc., resigned effective June 30, 2026, after 19 years of service. The disclosure centers on the departure of a named executive officer from a critical financial leadership position, which is material to investors assessing the company's governance and operational continuity. While the company notes it has initiated a CFO search, the principal disclosed action is the officer's resignation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-01
Item 2.01
Marchex completed its acquisition of 100% of Archenia's outstanding shares on July 1, 2026, pursuant to a Stock Purchase Agreement dated May 8, 2026. The transaction consideration consisted of $10 million in convertible promissory notes and contingent equity consideration of up to 4 million shares of Class B common stock based on revenue/EBITDA and integration targets.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
Marchex held a special meeting of stockholders on July 1, 2026, where stockholders approved the Stock Purchase Agreement and related Archenia acquisition transaction by approximately 99.9% under both the Simple Majority Vote and Majority of the Minority Vote requirements. Stockholders also approved adjournment of the meeting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
John R. Linker was appointed as Executive Vice President of Finance and Chief Financial Officer effective July 1, 2026, succeeding Gregory P. Rustowicz. The appointment includes a base salary of $600,000, a 70% target bonus, and 165% long-term equity incentive participation. Thomas Oddo was also promoted to Chief Accounting Officer with an associated equity increase.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-01
Item 1.01
Evergy Kansas Central and co-borrowers entered into a $3.5 billion master revolving credit facility on June 30, 2026, with Wells Fargo as administrative agent, while simultaneously terminating two prior credit facilities ($2.5 billion Amended and Restated Credit Agreement and $1 billion Delayed Draw Term Loan). This represents a material refinancing and restructuring of the company's credit arrangements.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-01
Item 8.01
Evergy Kansas Central issued $350 million in First Mortgage Bonds, 5.300% Series due 2036, pursuant to an underwriting agreement with major investment banks. This is a material creation of a direct financial obligation and represents a significant debt issuance that would affect a reasonable investor's assessment of the company's capital structure and financial position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-01
Item 5.02
The filing discloses both a director resignation (Andrew Levin) and the election of a new director (Breanna O'Reilly, Ph.D.) on the same date. While both events are present, the principal action emphasized in the disclosure is Dr. O'Reilly's election to the Board effective immediately, with detailed information about her compensation package (70,284 option grant at $13.36/share, $40,000 annual cash retainer, and future equity grants). The appointment is the forward-looking event and receives substantially more disclosure than the departure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-07-01
Item 3.03
Digital Realty completed the Blackstone Acquisition, which involved the creation of a new class of non-voting common stock (12.3 million shares) that automatically converted upon transfer, followed by an underwritten public offering of the converted shares. The transaction materially altered the company's capital structure and voting rights of existing shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-01
Item 2.02
The filing discloses Greenbrier's third fiscal quarter financial results for the period ended May 31, 2026, including revenue of $576.5M, net earnings of $18.9M ($0.60 diluted EPS), and EBITDA of $69.1M. The earnings release is furnished as Exhibit 99.1 and incorporated into Item 2.02, which is the standard Item for quarterly earnings disclosures. Material metrics such as gross margin improvement (230 basis points sequentially), lease fleet growth to 20,600 units, and updated fiscal 2026 guidance are disclosed.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-01
Item 2.02
Franklin Covey disclosed its third quarter fiscal 2026 financial results on July 1, 2026, reporting consolidated revenue of $67.8 million, net income of $3.1 million (versus a prior-year loss), Adjusted EBITDA of $8.3 million with 14% growth, and revised full-year fiscal 2026 guidance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-01
Item 3.02
MSD Investment Corp. issued 9,574,468 shares of common stock for approximately $225.0 million on June 26, 2026, pursuant to subscription agreements with stockholders. The issuance was made under Section 4(a)(2) of the Securities Act and Regulation D, relying on accredited investor representations. This is a classic unregistered equity issuance under Item 3.02, representing a material capital raise that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-01
Item 8.01
GATX exercised a call option on June 30, 2026 to acquire an additional interest in Blocker, thereby increasing its indirect ownership in the JV from 30% to approximately 33.535%. This represents a material acquisition activity under a pre-existing Call Option Agreement, with corresponding amendments to governance and capital provisions in the Blocker LLC Agreement. The transaction materially increases GATX's ownership stake and control rights in the joint venture.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 5.02
Ravi Thanawala was appointed as Executive Vice President and Chief Financial Officer effective August 3, 2026, with a compensation package including $1M base salary, $2.5M in target equity grants, and a $1M sign-on bonus. Michael Mathias transitioned to a non-officer Strategic Advisor role.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-01
Item 8.01
The Board declared a monthly dividend of $0.13589041 per share (reflecting a targeted annualized dividend of $1.60 per share) with a record date of July 31, 2026 and payment date of August 14, 2026. This is a routine but material dividend declaration by a REIT, which is a standard capital distribution to shareholders and would affect investor assessment of the company's capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-01
Item 8.01
The filing discloses a special dividend of Series O Convertible Preferred Stock paid on March 4, 2026, followed by the automatic conversion of all outstanding Series O Preferred Stock into Common Stock on June 25, 2026, at a conversion ratio of 3.209 shares of Common Stock per preferred share. This conversion resulted in 4,857,211 shares of Common Stock outstanding and an additional 839,000 shares issuable upon warrant exercise, representing substantial dilution to existing common shareholders. While the event involves both a dividend distribution and a conversion, the material impact centers on the dilutive issuance of common shares through the preferred stock conversion mechanism.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-01
Item 2.02
This is a clear earnings release disclosing Culp Inc.'s fourth quarter and full fiscal year 2026 financial results. The Item 2.02 filing explicitly states "Culp, Inc. issued a news release to announce financial results for its fourth quarter and fiscal year ended May 3, 2026," with the full press release attached as Exhibit 99.1. The disclosure includes consolidated net sales, gross profit, operating loss, net loss per share, and segment performance metrics, along with forward guidance for fiscal 2027.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-01
Item 1.01
Kohl's entered into Amendment No. 2 to its Revolving Credit Facility on June 30, 2026, which extends the maturity date by five years to June 30, 2031 and modifies pricing terms and borrowing base provisions. While this is technically an amendment to an existing credit facility rather than a new debt issuance, it represents a material modification of a direct financial obligation that extends the company's debt maturity profile and alters borrowing terms. This falls under debt_issuance as the most appropriate category for creation or material amendment of direct financial obligations, though the amendment nature (rather than new issuance) creates some ambiguity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-01
Item 1.01
Jade Biosciences entered into a material exclusive license agreement with Paragon Therapeutics on June 29, 2026, granting worldwide rights to develop and commercialize monospecific antibodies targeting an undisclosed therapeutic target. The agreement involves up to $22.0 million in development milestones and up to $20.1 million in sublicensing fees, plus royalties on future net sales. This is a strategic operational and commercial transaction material to the company's pipeline and business development, but does not constitute a merger, acquisition, or change of control (which would be classified as ma_activity), nor does it fit other specific financial or governance categories.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-01
Item 1.01
Nasdaq entered into an Amended and Restated Credit Agreement on June 30, 2026, establishing a $1.5 billion senior unsecured five-year revolving credit facility with Bank of America as administrative agent. This represents creation of a new direct financial obligation and material credit arrangement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-01
Item 5.07
Aon held its Annual Meeting of Shareholders on June 26, 2026, with voting results on seven proposals including election of 13 directors (approved), an advisory vote on executive compensation (not approved), ratification of auditors, and authorizations for share issuance and pre-emption rights.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-01
Item 8.01
The Board approved an increase to Aon's share repurchase program by $7.5 billion, bringing total authorization to approximately $8.3 billion, representing a material capital return to shareholders.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-01
EX-99.1
The announcement discloses compensatory arrangements agreed with Ron Edmonds in connection with his appointment as Interim Chief Financial Officer, including a USD$450,000 pro-rated base salary, short-term incentive up to 100% of fixed remuneration, and long-term incentive of USD$95,000 in director share rights subject to shareholder approval. This is a classic executive compensation disclosure under Item 5.02(e) equivalent, material to investors assessing executive costs and governance.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-01
Item 4.01
The filing discloses the dismissal of Deloitte & Touche LLP as the Company's independent registered public accounting firm on June 26, 2026, and the engagement of Cherry Bekaert LLP as the successor auditor. While the auditor reports contained no adverse opinions or disclaimers, they included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern, and material weaknesses in internal control over financial reporting remained unremediated as of December 31, 2025. This is a clear auditor change under Item 4.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-01
Item 1.01
The Company entered into an underwriting agreement on June 29, 2026 for the issuance and sale of $350 million aggregate principal amount of 6.100% Notes due 2031. This is a material creation of a direct financial obligation through debt issuance, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The size ($350M) and nature of the obligation (senior notes) make this material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
Ambarella held its Annual Meeting of shareholders on June 26, 2026, with voting results on four matters: election of three Class II directors (Bryant, Richardson, Schwarting), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and approval of the Amended and Restated 2021 Equity Incentive Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
Maurice Tulloch was appointed to the Board of Directors of Reinsurance Group of America, effective July 1, 2026. Tulloch is the former CEO of Aviva Group and brings extensive executive and operational expertise to strengthen the Board's oversight and global perspective.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-01
Item 1.01
Avalyn Pharma entered into a First Amendment to a sublease agreement expanding the leased premises from 8,774 to 13,708 rentable square feet with an increase in future minimum lease payments of approximately $924,000 over the remaining lease term. This is a material operational/real estate commitment that does not fit the specific categories of M&A, debt issuance, or other named financial events, making it an operational business arrangement material to investors assessing the company's capital commitments and facility footprint.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-07-01
Item 8.01
Talos Production Inc., a wholly owned subsidiary of Talos Energy, priced an offering of $800 million in aggregate principal amount of 8.000% second-priority senior secured notes due 2034, with net proceeds intended to fund a pending Gulf of America acquisition, redeem existing 2029 Notes, and pay related fees. The offering is expected to close on or about July 13, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-01
Item 5.07
This Item 5.07 disclosure reports the results of Quest Resource Holding Corp's 2026 Annual Meeting of Stockholders held on June 30, 2026, including voting outcomes on five proposals: election of two Class II directors, advisory vote on named executive officer compensation, ratification of auditor Semple, Marchal and Cooper, LLP, amendment to the 2024 Incentive Compensation Plan to increase shares by 600,000, and amendment to the 2024 Employee Stock Purchase Plan to increase shares by 150,000. All matters were approved by requisite stockholder vote, with detailed vote tallies provided for each proposal and director nominee.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-07-01
The 6-K announces a board-approved share repurchase program authorizing up to $10,000,000 in Class A ordinary share repurchases over 18 months, capped at 20% of outstanding shares. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return-of-capital program. The $10 million authorization and 20% cap represent material capital allocation decisions that would affect a reasonable investor's assessment of the company's capital strategy.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-01
The 6-K discloses results of a Class A Meeting and 2026 Annual Meeting of Shareholders held on June 29, 2026, with voting tallies for seven proposals including director elections, auditor ratification, share issuance and repurchase mandates, a reverse share split authorization (1:10 ratio), and voting rights variations for Class B shares. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the reverse split authorization and voting rights changes are material governance matters affecting share structure and shareholder control.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-01
EX-99.1
The press release announces the signing of "definitive binding agreements for the joint venture development" of a 770-room Hotel101 in Bangkok, Thailand. This constitutes entry into a material acquisition or joint venture arrangement. The project is expected to generate approximately US$58 million in sales revenue and represents a significant milestone in the company's global expansion strategy, making it material to investors assessing the registrant's growth trajectory and capital deployment.
View raw filing on EDGAR →
6-K
Earnings release
confidence 25%
filed 2026-07-01
EX-99.1
This is a clinical trial results announcement for Namodenoson in a Phase 2a pancreatic cancer study. While it discloses positive safety and survival outcomes, it is not a financial earnings release (no quarterly or annual financial results). The disclosure is material to investors as it reports clinical progress on a key pipeline asset, but the event_type taxonomy does not contain a specific category for clinical trial results or product development milestones. This is an operational/strategic disclosure about drug development progress that does not fit neatly into the provided categories.
View raw filing on EDGAR →